CRP test endorsed
This article was originally published in The Gray Sheet
Executive Summary
American Heart Association and CDC recommend high-sensitivity C-reactive protein testing as an option to facilitate heart disease risk assessment and potential treatment selection when other factors project a 10-year CHD risk of 10%-20%. Published in the Jan. 28 issue of Circulation, guidelines suggest additional studies of the systemic inflammation marker test are needed to clarify appropriate use. A recent 28,000-patient study by Paul Ridker, MD, Brigham and Women's Hospital, Boston, et al., showed the roughly $20 CRP test is a stronger predictor of cardiovascular events than LDL cholesterol ("The Gray Sheet" Nov. 18, 2002, In Brief). CRP test product makers include Bayer, Beckman Coulter, Dade Behring and Diagnostic Products...
You may also be interested in...
Heart health marker
C-reactive protein is a stronger predictor of cardiovascular events than low-density lipoprotein (LDL) cholesterol, according to a study led by Paul Ridker, MD, Brigham and Women's Hospital in Boston, reported in the Nov. 14 issue of the New England Journal of Medicine. The study followed 27,939 apparently healthy American women for eight years, correlating LDL cholesterol and C-reactive protein levels to incidence of myocardial infarction, ischemic stroke, coronary revascularization and cardiovascular-related death...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.